Lantheus Holdings, Inc. $LNTH is Reinhart Partners LLC.’s 2nd Largest Position

Reinhart Partners LLC. increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,599,379 shares of the medical equipment provider’s stock after purchasing an additional 34,501 shares during the quarter. Lantheus makes up 4.1% of Reinhart Partners LLC.’s investment portfolio, making the stock its 2nd largest holding. Reinhart Partners LLC. owned about 2.46% of Lantheus worth $177,437,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc grew its stake in Lantheus by 33.0% in the second quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock valued at $65,000 after acquiring an additional 146 shares during the period. Abel Hall LLC raised its position in shares of Lantheus by 4.6% during the first quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock worth $297,000 after purchasing an additional 172 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 197 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Lantheus by 6.4% during the 2nd quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock valued at $371,000 after purchasing an additional 202 shares in the last quarter. Finally, Blue Trust Inc. grew its position in shares of Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on LNTH shares. TD Cowen downgraded shares of Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the stock from $110.00 to $102.50 in a report on Monday. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research report on Wednesday, July 29th. Brookline Capital Markets lowered shares of Lantheus from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Truist Financial cut shares of Lantheus from a “buy” rating to a “hold” rating and cut their price objective for the company from $125.00 to $102.50 in a research report on Monday. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $108.11.

Lantheus Trading Down 0.1%

NASDAQ:LNTH opened at $100.95 on Friday. Lantheus Holdings, Inc. has a twelve month low of $49.67 and a twelve month high of $111.86. The company has a quick ratio of 2.64, a current ratio of 3.06 and a debt-to-equity ratio of 0.43. The business has a 50 day moving average price of $104.09 and a two-hundred day moving average price of $87.98. The company has a market cap of $6.57 billion, a P/E ratio of 24.38 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same period last year, the company earned $1.57 earnings per share. The firm’s revenue was up 2.7% compared to the same quarter last year. As a group, analysts expect that Lantheus Holdings, Inc. will post 4.5 EPS for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.